Precision closes in on what could become the first 'off-the-shelf' CAR-T cell therapy
PharmaVoice
JULY 7, 2022
Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.
PharmaVoice
JULY 7, 2022
Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.
Pharmacy Times
JULY 8, 2022
Findings suggest that the HER2 L755S mutation plays a role in the aggressiveness of lobular breast cancer observed in the clinic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 8, 2022
The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and its spend in this area has created a multibillion-dollar market for AI technologies. That’s the conclusion of a GlobalData report , which notes that AI is being used to enhance computer-aided drug design (CADD) in a bid to reduce the time and costs involved in getting a new drug to market.
Pharmaceutical Technology
JULY 6, 2022
Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7. Elsewhere, San Diego, California-based Heron Therapeutics announced restructuring and layoffs for 34% of its workforce.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaVoice
JULY 6, 2022
Ratings agency Moody’s lays out the risk exposure for industry leaders.
Pharmacy Times
JULY 8, 2022
David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
JULY 5, 2022
AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers. The big pharma is paying $100 million upfront for the company, and offering up to $805 million in milestone payments if TeneoTwo’s drug candidates meet development objectives, plus up to $360 million if they hit sales targets.
PharmaVoice
JULY 7, 2022
Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.
Pharmacy Times
JULY 7, 2022
People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.
Pharmaceutical Technology
JULY 4, 2022
GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. In April this year, GSK entered an agreement for the acquisition of Sierra Oncology for $55 per share. The conclusion of the deal comes after the shareholders of Sierra Oncology approved the takeover on 29 June this year.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JULY 5, 2022
Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a global health initiative launched by the company last year. The medicines – which include insulin, oral diabetes agent glibenclamide and cancer chemotherapy oxaliplatin – will be sold under a new Impact brand and are all classed as essential medicines by the World Health Organisation (WHO).
PharmaVoice
JULY 6, 2022
From M&Ms to biotech, the chief financial officer's sweet tooth for taking risks is paying off.
Pharmacy Times
JULY 8, 2022
Simple changes to each day can improve motivation and wellness for pharmacists.
European Pharmaceutical Review
JULY 5, 2022
After more than 20 years of environmental action, Pfizer has committed to further reduce its greenhouse gas (GHG) emissions and aims to achieve the voluntary Net-Zero Standard by 2040 – a full 10 years ahead of the standard’s proposed timeline. To achieve these goals, Pfizer aims to decrease its GHG emissions by 95 percent and its value chain emissions by 90 percent from 2019 levels by 2040.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JULY 4, 2022
GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the first partners have joined the initiative. The asset management arm of Swiss back UBS has formed a joint venture with property developer Reef Group that will develop the 33-acre campus in Stevenage, Hertfordshire.
PharmaVoice
JULY 5, 2022
In a unanimous decision, a CDC committee calls for a preferential flu vaccine recommendation for people aged 65 and older for the first time.
Pharmacy Times
JULY 3, 2022
If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. Following the option exercise, Vir will receive the option exercise fee, regulatory and commercial milestone payments as well as tiered royalties on net product sales from Brii Bio.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JULY 5, 2022
Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. Yet evidence from research studies and a survey with 4,000+ atopic dermatitis patients conducted by Clariness shows that this ‘race to recruit’ is actually not the primary reason for the growing discontinuation rate of atopic dermatitis trials.
PharmaVoice
JULY 5, 2022
AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.
Pharmacy Times
JULY 7, 2022
Trauma informed care has had an impact on the public health spectrum for years, especially with what has happened on a global front.
Pharmaceutical Technology
JULY 7, 2022
Brii Biosciences and TSB Therapeutics have commercially launched a long-acting neutralising antibody therapy combination, amubarvimab/romlusevimab, for Covid-19 in China. The two non-competing SARS-CoV-2 monoclonal neutralising antibodies, amubarvimab and romlusevimab are obtained from convalesced Covid-19 patients. The company developed these antibodies in partnership with Tsinghua University and the 3rd People’s Hospital of Shenzhen.
pharmaphorum
JULY 5, 2022
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness.
European Pharmaceutical Review
JULY 5, 2022
The Impact ® brand includes 30 Sanofi medicines and covers a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer. Medicines include insulin, glibenclamide and oxaliplatin, the company said. Sanofi has also established an Impact fund to support startup companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. .
Pharmacy Times
JULY 8, 2022
Autologous stem cell transplantation was underutilized in community settings for mantle cell lymphoma.
Pharmaceutical Commerce
JULY 8, 2022
How did the industry get here and what alternatives can be sought out?
pharmaphorum
JULY 7, 2022
Pfizer is still waiting for the green light to complete an acquisition of digital health company ResApp, a deal that looks even better now that its smartphone app for people with obstructive sleep apnoea (OSA) has been approved by the FDA. Brisbane, Australia-based ResApp has claimed a 510(k) clearance for SleepCheckRx as a prescription-only digital therapy in the software-as-a-medical device (SaMD) category, clearing the path for a commercial launch in the US.
PharmExec
JULY 8, 2022
Continent has shed its ‘emerging’ status on world biopharma stage.
Pharmacy Times
JULY 8, 2022
Hypervitaminosis D, a condition characterized by elevated vitamin D levels, is associated with potential serious health issues, such as psychosis, abdominal pain, vomiting, pancreatitis, and renal failure.
European Pharmaceutical Review
JULY 7, 2022
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . “Eric brings nearly 20 years of leadership roles with a proven track record in a variety of R&D functions for global pharmaceutical companies, and has a successful record of accomplishment fostering productive collaborations with
pharmaphorum
JULY 5, 2022
Cancer drugs will be flown from a facility in Portsmouth to a hospital on the Isle of Wight by drone, in the first pilot study of the technology by NHS England. The trial – announced this morning and said to be the first of its type worldwide – will mean that the lifesaving treatment can be picked up and dropped off to patients on the same day, said NHS chief executive Amanda Pritchard.
Pharmaceutical Technology
JULY 6, 2022
Europe was the fastest growing region for data analytics hiring among pharmaceutical industry companies in the three months ending May. The number of roles in Europe made up 11.8% of total data analytics jobs - up from 11.1% in the same quarter last year. That was followed by North America, which saw a -0.4 year-on-year percentage point change in data analytics roles.
Pharmacy Times
JULY 8, 2022
ProAir Digihaler Inhalation Powder is indicated for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Let's personalize your content